6d • General discussion
The Peptide Shift Has Started
Right now (as of 2026), the FDA is starting to revisit a lot of peptides that were previously restricted, but nothing major has fully changed yet.
They’re looking at allowing compounding on a group of peptides (around 12–14), including:
- BPC-157
- GHK-Cu
- TB-500
- LL-37
- Melanotan II
- Dihexa
- PEG-MGF
All of these are getting attention for things like tissue repair, recovery, antimicrobial effects, and cognition—but most of them still don’t have full FDA-level clinical trials.
On the other side, the GLP-1s:
- Semaglutide
- Tirzepatide
Those are already fully FDA-approved and validated for weight loss and metabolic use.
There are also newer peptides being developed (like antibiotic-targeting ones), but those are still in early stages.
Big picture:
- The FDA is considering opening things up
- Most of these peptides are still in a restricted category right now
- Compounding isn’t officially allowed on most of them yet
- More decisions are expected (meetings through 2026–2027)
So overall:
Things are moving, but we’re not there yet.
1
2 comments
The Peptide Shift Has Started
skool.com/bioopt
For adults 35+ ready to build muscle, burn fat, and optimize hormones. Aging is inevitable. Decline isn’t. Train smarter. Optimize everything.
Leaderboard (30-day)
1
+5
2
+5
3
+4
4
+4
5
+3
Powered by